Roche's Tecentriq Meets Primary Endpoint in Phase 3 Lung Cancer Study
Roche's Tecentriq Meets Primary Endpoint in Phase 3 Lung Cancer Study
*DJ Roche: Phase 3 Study Shows Tecentriq Helped People With Early Lung Cancer Live Longer Without Their Disease Returning
(MORE TO FOLLOW) Dow Jones Newswires
March 22, 2021 02:03 ET (06:03 GMT)
*DJ Roche: Study Met Its Primary Endpoint of Disease-Free Survival at Interim Analysis
(MORE TO FOLLOW) Dow Jones Newswires
March 22, 2021 02:05 ET (06:05 GMT)
*DJ Roche: Tecentriq Showed Statistically Significant Improvement in Disease-Free Survival as Adjuvant Therapy Following Surgery and Chemotherapy
(END) Dow Jones Newswires
March 22, 2021 02:05 ET (06:05 GMT)
DJ Roche's Tecentriq Meets Primary Endpoint in Phase 3 Lung Cancer Study
By Cecilia Butini
Roche Holding AG said Monday that a Phase 3 study on its monoclonal antibody drug Tecentriq met the primary endpoint of providing disease-free survival to lung cancer patients.
The Swiss pharmaceutical major said the drug showed a statistically significant improvement in disease-free survival for patients suffering non-small-cell lung cancer after surgery and chemotherapy.
Tecentriq is already approved for five indications for different types of lung cancer in markets around the world, Roche said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
March 22, 2021 02:15 ET (06:15 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
*DJ Roche: Phase 3 Study Shows Tecentriq Helped People With Early Lung Cancer Live Longer Without Their Disease Returning
*DJ罗氏：第三阶段研究显示，Tecentriq帮助早期肺癌患者延长了寿命，而不会复发
(MORE TO FOLLOW) Dow Jones Newswires
(更多后续报道)道琼斯通讯社
March 22, 2021 02:03 ET (06:03 GMT)
2021年3月22日东部时间02：03(格林威治时间06：03)
*DJ Roche: Study Met Its Primary Endpoint of Disease-Free Survival at Interim Analysis
*DJ罗氏：研究在中期分析中遇到其无病生存的主要终点
(MORE TO FOLLOW) Dow Jones Newswires
(更多后续报道)道琼斯通讯社
March 22, 2021 02:05 ET (06:05 GMT)
2021年3月22日东部时间02：05(格林尼治标准时间06：05)
*DJ Roche: Tecentriq Showed Statistically Significant Improvement in Disease-Free Survival as Adjuvant Therapy Following Surgery and Chemotherapy
*DJ罗氏：Tecentriq在手术和化疗后作为辅助治疗的无病生存方面显示出统计上的显著改善
(END) Dow Jones Newswires
(完)道琼通讯社
March 22, 2021 02:05 ET (06:05 GMT)
2021年3月22日东部时间02：05(格林尼治标准时间06：05)
DJ Roche's Tecentriq Meets Primary Endpoint in Phase 3 Lung Cancer Study
DJ罗氏公司的Tecentriq公司在3期肺癌研究中遇到主要终点
By Cecilia Butini
塞西莉亚·布蒂尼(Cecilia Butini)
Roche Holding AG said Monday that a Phase 3 study on its monoclonal antibody drug Tecentriq met the primary endpoint of providing disease-free survival to lung cancer patients.
罗氏控股公司(Roche Holding AG)周一表示，其单克隆抗体药物Tecentriq的第三阶段研究达到了为肺癌患者提供无病生存的主要终点。
The Swiss pharmaceutical major said the drug showed a statistically significant improvement in disease-free survival for patients suffering non-small-cell lung cancer after surgery and chemotherapy.
这位瑞士制药专业人士表示，该药物显示，在手术和化疗后，非小细胞肺癌患者的无病生存率在统计上有显着改善。
Tecentriq is already approved for five indications for different types of lung cancer in markets around the world, Roche said.
罗氏说，Tecentriq已经在世界各地的市场上被批准用于不同类型肺癌的五种适应症。
Write to Cecilia Butini at cecilia.butini@wsj.com
写信给塞西莉亚·布蒂尼(Cecilia Butini)，电子邮件：cecilia.butini@wsj.com
(END) Dow Jones Newswires
(完)道琼通讯社
March 22, 2021 02:15 ET (06:15 GMT)
2021年3月22日东部时间02：15(格林尼治标准时间06：15)
Copyright (c) 2021 Dow Jones & Company, Inc.
版权所有(C)2021年道琼斯公司
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧